SynBioBeta Speaker

Peyton Greenside

BigHat Biosciences

CEO & Co-Founder

Peyton Greenside is the co-founder and CEO of BigHat Biosciences, a Bay Area biotechnology company pioneering an ML-driven platform to accelerate the design of next-generation antibodies and other therapeutic proteins. She holds a PhD from Stanford University, an MPhil in Computational Biology from the University of Cambridge, and a BA in Applied Mathematics from Harvard.

Sessions Featuring

Peyton

This Year

Breakout Session

•

3:30 PM

-

4:15 PM

Tools & Tech

Beyond Nature’s Alphabet: The Rise of Programmable Biomolecules

Biology has long relied on a limited molecular vocabulary shaped by natural evolution. Today, that alphabet is expanding. Advances in expanded genetic codes, non-canonical amino acids, macrocycles, de novo design, and AI-guided protein engineering are enabling scientists to create biomolecules with properties and functions that nature never evolved. This session explores the rise of programmable biomolecules at the intersection of biology, chemistry, and computation. Rather than simply optimizing existing proteins, researchers are building entirely new classes of functional molecules with novel architectures, chemistries, and therapeutic potential. From next-generation biologics to hybrid molecular scaffolds, the discussion will examine how the field is moving beyond nature’s defaults and toward a future where biomolecules can be designed with increasing precision, flexibility, and intent.

Featuring

Frank Poelwijk

Generate:Biomedicines

VP, Head of Prototyping Lab

Ola Wlodek

Constructive Bio

CEO

Leader in Non-Canonical Amino Acids and genome design

Peyton Greenside

BigHat Biosciences

CEO & Co-Founder

Bryan Walsh

Vox Media

Senior Editorial Dir.

Future Perfect editor covering climate, existential risk, tomorrow.

Breakout Session

•

3:30 PM

-

4:15 PM

Tools & Tech

Beyond Nature’s Alphabet: The Rise of Programmable Biomolecules

Biology has long relied on a limited molecular vocabulary shaped by natural evolution. Today, that alphabet is expanding. Advances in expanded genetic codes, non-canonical amino acids, macrocycles, de novo design, and AI-guided protein engineering are enabling scientists to create biomolecules with properties and functions that nature never evolved. This session explores the rise of programmable biomolecules at the intersection of biology, chemistry, and computation. Rather than simply optimizing existing proteins, researchers are building entirely new classes of functional molecules with novel architectures, chemistries, and therapeutic potential. From next-generation biologics to hybrid molecular scaffolds, the discussion will examine how the field is moving beyond nature’s defaults and toward a future where biomolecules can be designed with increasing precision, flexibility, and intent.

Featuring

Frank Poelwijk

Generate:Biomedicines

VP, Head of Prototyping Lab

Ola Wlodek

Constructive Bio

CEO

Leader in Non-Canonical Amino Acids and genome design

Peyton Greenside

BigHat Biosciences

CEO & Co-Founder

Bryan Walsh

Vox Media

Senior Editorial Dir.

Future Perfect editor covering climate, existential risk, tomorrow.

Previous Speakers Include